Halozyme Therapeutics, Inc. (HALO)
USD 57.78
(-3.33%)
USD 57.78
(-3.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 337.57 Million USD | 26.18% |
| 2022 | 267.53 Million USD | -3.03% |
| 2021 | 275.9 Million USD | 91.26% |
| 2020 | 144.25 Million USD | 313.36% |
| 2019 | -67.61 Million USD | 2.48% |
| 2018 | -69.33 Million USD | -185.59% |
| 2017 | 81 Million USD | 197.35% |
| 2016 | -83.21 Million USD | -203.11% |
| 2015 | -27.45 Million USD | 56.45% |
| 2014 | -63.03 Million USD | 21.63% |
| 2013 | -80.43 Million USD | -49.99% |
| 2012 | -53.62 Million USD | -170.3% |
| 2011 | -19.83 Million USD | 63.44% |
| 2010 | -54.25 Million USD | 7.19% |
| 2009 | -58.45 Million USD | -15.91% |
| 2008 | -50.43 Million USD | -79.16% |
| 2007 | -28.15 Million USD | -80.65% |
| 2006 | -15.58 Million USD | -14.91% |
| 2005 | -13.56 Million USD | -49.23% |
| 2004 | -9.08 Million USD | -11390.37% |
| 2003 | -79.09 Thousand USD | -100.8% |
| 2002 | -39.38 Thousand USD | 0.8% |
| 2001 | -39.7 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 117.23 Million USD | 22.71% |
| 2024 Q1 | 95.54 Million USD | -5.44% |
| 2024 Q3 | 163.19 Million USD | 39.21% |
| 2023 Q2 | 94.45 Million USD | 75.57% |
| 2023 Q3 | 88.27 Million USD | -6.54% |
| 2023 Q4 | 101.03 Million USD | 14.45% |
| 2023 FY | 337.57 Million USD | 26.18% |
| 2023 Q1 | 53.8 Million USD | -27.79% |
| 2022 Q3 | 83.29 Million USD | 144.54% |
| 2022 Q1 | 75.67 Million USD | 33.85% |
| 2022 Q2 | 34.06 Million USD | -54.99% |
| 2022 FY | 267.53 Million USD | -3.03% |
| 2022 Q4 | 74.5 Million USD | -10.54% |
| 2021 FY | 275.9 Million USD | 91.26% |
| 2021 Q4 | 56.53 Million USD | -25.21% |
| 2021 Q3 | 75.58 Million USD | -18.77% |
| 2021 Q2 | 93.04 Million USD | 83.4% |
| 2021 Q1 | 50.73 Million USD | -34.64% |
| 2020 Q2 | 29.55 Million USD | 1017.0% |
| 2020 Q1 | -3.22 Million USD | 89.95% |
| 2020 Q3 | 40.29 Million USD | 36.35% |
| 2020 FY | 144.25 Million USD | 313.36% |
| 2020 Q4 | 77.62 Million USD | 92.62% |
| 2019 Q2 | -13.97 Million USD | -571.24% |
| 2019 Q3 | -24.53 Million USD | -75.55% |
| 2019 Q4 | -32.06 Million USD | -30.67% |
| 2019 FY | -67.61 Million USD | 2.48% |
| 2019 Q1 | 2.96 Million USD | 4277.46% |
| 2018 Q1 | -23.71 Million USD | -118.83% |
| 2018 FY | -69.33 Million USD | -185.59% |
| 2018 Q4 | -71 Thousand USD | 99.72% |
| 2018 Q3 | -25.47 Million USD | -26.91% |
| 2018 Q2 | -20.07 Million USD | 15.35% |
| 2017 Q4 | 125.92 Million USD | 1459.11% |
| 2017 Q3 | 8.07 Million USD | 131.7% |
| 2017 Q2 | -25.47 Million USD | 7.44% |
| 2017 Q1 | -27.52 Million USD | -21.93% |
| 2017 FY | 81 Million USD | 197.35% |
| 2016 Q3 | -22.74 Million USD | -4.7% |
| 2016 Q4 | -22.57 Million USD | 0.74% |
| 2016 FY | -83.21 Million USD | -203.11% |
| 2016 Q2 | -21.72 Million USD | -34.35% |
| 2016 Q1 | -16.16 Million USD | -395.86% |
| 2015 Q4 | 5.46 Million USD | 123.52% |
| 2015 Q3 | -23.23 Million USD | -649.21% |
| 2015 Q2 | 4.23 Million USD | 130.41% |
| 2015 Q1 | -13.91 Million USD | -261.23% |
| 2015 FY | -27.45 Million USD | 56.45% |
| 2014 Q2 | -14.94 Million USD | 40.76% |
| 2014 FY | -63.03 Million USD | 21.63% |
| 2014 Q1 | -25.21 Million USD | -18.27% |
| 2014 Q4 | -3.85 Million USD | 79.76% |
| 2014 Q3 | -19.02 Million USD | -27.35% |
| 2013 Q3 | -18.49 Million USD | 16.4% |
| 2013 FY | -80.43 Million USD | -49.99% |
| 2013 Q1 | -18.49 Million USD | -319.68% |
| 2013 Q4 | -21.32 Million USD | -15.3% |
| 2013 Q2 | -22.12 Million USD | -19.6% |
| 2012 Q4 | -4.4 Million USD | 78.0% |
| 2012 Q1 | -15.14 Million USD | 17.84% |
| 2012 Q3 | -20.02 Million USD | -42.58% |
| 2012 Q2 | -14.04 Million USD | 7.21% |
| 2012 FY | -53.62 Million USD | -170.3% |
| 2011 FY | -19.83 Million USD | 63.44% |
| 2011 Q1 | -9.65 Million USD | 45.99% |
| 2011 Q2 | 3.09 Million USD | 132.05% |
| 2011 Q3 | 5.15 Million USD | 66.44% |
| 2011 Q4 | -18.42 Million USD | -457.63% |
| 2010 Q4 | -17.88 Million USD | -43.83% |
| 2010 FY | -54.25 Million USD | 7.19% |
| 2010 Q3 | -12.43 Million USD | -2.32% |
| 2010 Q2 | -12.15 Million USD | -3.09% |
| 2010 Q1 | -11.78 Million USD | 7.01% |
| 2009 Q1 | -14.75 Million USD | 13.32% |
| 2009 FY | -58.45 Million USD | -15.91% |
| 2009 Q2 | -17.08 Million USD | -15.75% |
| 2009 Q4 | -12.67 Million USD | 9.06% |
| 2009 Q3 | -13.93 Million USD | 18.4% |
| 2008 Q3 | -11.19 Million USD | 1.54% |
| 2008 FY | -50.43 Million USD | -79.16% |
| 2008 Q4 | -17.02 Million USD | -52.03% |
| 2008 Q2 | -11.37 Million USD | -4.99% |
| 2008 Q1 | -10.83 Million USD | -9.13% |
| 2007 Q3 | -8.3 Million USD | -42.47% |
| 2007 Q4 | -9.92 Million USD | -19.47% |
| 2007 Q1 | -4.08 Million USD | 12.6% |
| 2007 FY | -28.15 Million USD | -80.65% |
| 2007 Q2 | -5.83 Million USD | -42.94% |
| 2006 Q1 | -3.67 Million USD | -2.63% |
| 2006 FY | -15.58 Million USD | -14.91% |
| 2006 Q3 | -3.82 Million USD | -12.04% |
| 2006 Q4 | -4.66 Million USD | -22.03% |
| 2006 Q2 | -3.41 Million USD | 7.03% |
| 2005 Q2 | -2.94 Million USD | 9.94% |
| 2005 Q4 | -3.57 Million USD | 4.96% |
| 2005 FY | -13.56 Million USD | -49.23% |
| 2005 Q3 | -3.76 Million USD | -27.84% |
| 2005 Q1 | -3.27 Million USD | -29.39% |
| 2004 Q4 | -2.52 Million USD | 22.53% |
| 2004 Q1 | -1.2 Million USD | -2106.86% |
| 2004 Q2 | -2.08 Million USD | -73.01% |
| 2004 FY | -9.08 Million USD | -11390.37% |
| 2004 Q3 | -3.26 Million USD | -56.2% |
| 2003 FY | -79.09 Thousand USD | -100.8% |
| 2003 Q1 | -9074.00 USD | 56.5% |
| 2003 Q2 | -4849.00 USD | 46.56% |
| 2003 Q4 | -54.71 Thousand USD | -478.29% |
| 2003 Q3 | -9462.00 USD | -95.13% |
| 2002 Q3 | -12.61 Thousand USD | 30.99% |
| 2002 Q1 | 12.35 Thousand USD | 0.0% |
| 2002 Q4 | -20.86 Thousand USD | -65.43% |
| 2002 FY | -39.38 Thousand USD | 0.8% |
| 2002 Q2 | -18.27 Thousand USD | -247.87% |
| 2001 FY | -39.7 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 242.312% |
| Alkermes plc | 414.12 Million USD | 18.484% |
| Agenus Inc. | -159.54 Million USD | 311.58% |
| Aptorum Group Limited | -10.52 Million USD | 3307.863% |
| Ardelyx, Inc. | -63.27 Million USD | 633.495% |
| Dyadic International, Inc. | -8.22 Million USD | 4201.88% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 28419.966% |
| Lantern Pharma Inc. | -17.87 Million USD | 1988.254% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 1780.326% |
| Novavax, Inc. | -566.51 Million USD | 159.588% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 562.563% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 510.694% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 1838.413% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 3295.816% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 735.417% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 188.719% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 1488.816% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 991.426% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 361.71% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 502.286% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 2024.705% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 867.039% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 1458.775% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 342.805% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 219.633% |
| AlloVir, Inc. | -181.33 Million USD | 286.165% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 264.669% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 1253.784% |
| Bicycle Therapeutics plc | -189.94 Million USD | 277.721% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 296.513% |
| ChromaDex Corporation | -5.59 Million USD | 6129.184% |
| Chimerix, Inc. | -93.06 Million USD | 462.729% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 848.878% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 390.864% |
| CRISPR Therapeutics AG | -222.53 Million USD | 251.693% |
| Precision BioSciences, Inc. | -43.73 Million USD | 871.845% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 277.194% |
| Fortress Biotech, Inc. | -142.34 Million USD | 337.157% |
| Fortress Biotech, Inc. | -142.34 Million USD | 337.157% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 445.542% |
| ImmuCell Corporation | -5.74 Million USD | 5972.815% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 351.117% |
| Immix Biopharma, Inc. | -16.14 Million USD | 2191.392% |
| Incyte Corporation | 620.52 Million USD | 45.599% |
| Innoviva, Inc. | 176.7 Million USD | -91.034% |
| IO Biotech, Inc. | -91.44 Million USD | 469.163% |
| Jaguar Health, Inc. | -34.29 Million USD | 1084.439% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 298.642% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -2726.779% |
| ContextLogic Inc. | -328 Million USD | 202.919% |
| MiMedx Group, Inc. | 37.11 Million USD | -809.511% |
| MEI Pharma, Inc. | 14.54 Million USD | -2221.373% |
| NextCure, Inc. | -67.63 Million USD | 599.097% |
| Onconetix, Inc. | -36.03 Million USD | 1036.805% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 909.258% |
| Opthea Limited | -191.84 Million USD | 275.964% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 12367.277% |
| Vaxcyte, Inc. | -468.04 Million USD | 172.125% |
| PDS Biotechnology Corporation | -43.04 Million USD | 884.231% |
| Precigen, Inc. | -88.92 Million USD | 479.625% |
| Pharming Group N.V. | -4.87 Million USD | 7018.146% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 301.763% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 1234.474% |
| PureTech Health plc | -146.19 Million USD | 330.9% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 1747.426% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 243.284% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 1488.816% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 223.2% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 1251.933% |
| Acelyrin, Inc. | -422.06 Million USD | 179.982% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 2617979.571% |
| Summit Therapeutics Inc. | -89.73 Million USD | 476.186% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 1010.787% |
| Senti Biosciences, Inc. | -92.72 Million USD | 464.051% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 394.123% |
| Elevation Oncology, Inc. | -45.44 Million USD | 842.819% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 1085.129% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 8663.417% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 10775.965% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 1122.301% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 4070.992% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 596.462% |
| Seer, Inc. | -103.46 Million USD | 426.275% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 613.35% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 569.289% |
| ESSA Pharma Inc. | -32.13 Million USD | 1150.516% |
| GlycoMimetics, Inc. | -39.27 Million USD | 959.507% |
| GT Biopharma, Inc. | -13.57 Million USD | 2586.55% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 253.988% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 829.795% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -288.856% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 694.75% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 755.407% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 3496.922% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 166.937% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 4993.795% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 765.918% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 230.007% |
| Aptose Biosciences Inc. | -52.35 Million USD | 744.767% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 2440.887% |
| Soligenix, Inc. | -7.69 Million USD | 4485.251% |
| Century Therapeutics, Inc. | -146.54 Million USD | 330.354% |
| Kura Oncology, Inc. | -165.8 Million USD | 303.598% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 461.204% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 4157.868% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 13702.865% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 5306.262% |
| Autolus Therapeutics plc | -195.02 Million USD | 273.09% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 498.755% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 558.274% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 1697.227% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 248.688% |
| GRI Bio, Inc. | -11.38 Million USD | 3064.556% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 7575.538% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 357.311% |
| IGM Biosciences, Inc. | -263.46 Million USD | 228.131% |
| INmune Bio, Inc. | -29.74 Million USD | 1235.046% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 405.179% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 986.595% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 2212.563% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 2240.497% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 652.512% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 413.958% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 222.307% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 266.13% |
| Verastem, Inc. | -92.08 Million USD | 466.594% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 816.185% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 283.32% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 385.161% |
| Histogen Inc. | -10.64 Million USD | 3271.794% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 2281.844% |
| Surrozen, Inc. | -45.78 Million USD | 837.383% |
| Organovo Holdings, Inc. | -15.08 Million USD | 2337.664% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 6731.795% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 669.443% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 758.116% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 1435.34% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 4522.651% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 297.086% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 796.777% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 531.653% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 2317.85% |
| Apollomics, Inc. | -54.83 Million USD | 715.629% |
| Amarin Corporation plc | -67.58 Million USD | 599.458% |
| Mesoblast Limited | -58.79 Million USD | 674.164% |
| Turnstone Biologics Corp. | -59.03 Million USD | 671.849% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 303.935% |
| Synaptogenix, Inc. | -8.31 Million USD | 4160.379% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 2414.37% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 468.165% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 7145.318% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 3922.5% |
| Exelixis, Inc. | 170.88 Million USD | -97.545% |
| Better Therapeutics, Inc. | -38.26 Million USD | 982.27% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 317.701% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 165.279% |
| NLS Pharmaceutics AG | -11.8 Million USD | 2959.085% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 4297.686% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 1225.509% |
| Gritstone bio, Inc. | -154.63 Million USD | 318.305% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 590.225% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 2071.459% |
| Avid Bioservices, Inc. | -18.67 Million USD | 1907.335% |
| Insmed Incorporated | -709.62 Million USD | 147.571% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 2251.552% |
| MediWound Ltd. | -15.29 Million USD | 2307.809% |
| OmniAb, Inc. | -69.41 Million USD | 586.285% |
| Alector, Inc. | -151.74 Million USD | 322.469% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 412.618% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 747.338% |
| Zai Lab Limited | -366.57 Million USD | 192.089% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 206.565% |
| Aura Biosciences, Inc. | -84.99 Million USD | 497.188% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 237.505% |
| Immunic, Inc. | -99.22 Million USD | 440.217% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 335.805% |
| Veracyte, Inc. | -85.79 Million USD | 493.466% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 219.786% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 2475.609% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 5000.938% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 1896.312% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 41.655% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 1426.264% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -769.991% |
| TG Therapeutics, Inc. | 20.63 Million USD | -1536.088% |
| Galecto, Inc. | -39.9 Million USD | 945.944% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 902.334% |
| Fortrea Holdings Inc. | 63.1 Million USD | -434.983% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 340.36% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 1268.966% |
| XBiotech Inc. | -37.51 Million USD | 999.957% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 590.225% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 602.941% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 412.841% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 1414.95% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 733.442% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 159.306% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 530.074% |
| Vaxxinity, Inc. | -58.28 Million USD | 679.178% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 425.501% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 1616.973% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 490.638% |
| NexImmune, Inc. | -29.19 Million USD | 1256.373% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 6106.514% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 2415.104% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 91.659% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 1425.952% |
| Scopus BioPharma Inc. | -11.71 Million USD | 2981.584% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 365.677% |
| Ainos, Inc. | -13.2 Million USD | 2656.14% |
| Pluri Inc. | -22.15 Million USD | 1623.486% |
| Prothena Corporation plc | -191.03 Million USD | 276.707% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 344.552% |
| Celularity Inc. | -192.28 Million USD | 275.557% |
| Rallybio Corporation | -78.93 Million USD | 527.677% |
| Cue Biopharma, Inc. | -52.14 Million USD | 747.326% |
| MeiraGTx Holdings plc | -137.06 Million USD | 346.295% |
| Omeros Corporation | -164.53 Million USD | 305.175% |
| Humacyte, Inc. | -100.04 Million USD | 437.415% |
| Immunocore Holdings plc | -59.64 Million USD | 665.934% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 1918.923% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 1478.81% |
| Blueprint Medicines Corporation | -486.27 Million USD | 169.42% |
| CalciMedica, Inc. | -21.87 Million USD | 1643.195% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 552.148% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 356.74% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 297.072% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 203.265% |
| Pulmatrix, Inc. | -14.74 Million USD | 2390.19% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 1044.395% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 479.869% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 165.511% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 599.732% |
| Cytokinetics, Incorporated | -496.2 Million USD | 168.031% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 1080.778% |
| Nutriband Inc. | -4.87 Million USD | 7028.964% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 874.022% |
| Vor Biopharma Inc. | -126.03 Million USD | 367.839% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 92.042% |
| Evogene Ltd. | -26.39 Million USD | 1379.125% |
| ProKidney Corp. | -151.52 Million USD | 322.789% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 623.087% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 4488.499% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 155.58% |
| CorMedix Inc. | -48.95 Million USD | 789.521% |
| BioLineRx Ltd. | -49.69 Million USD | 779.305% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 395.669% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 986.673% |
| Atai Life Sciences N.V. | -125.47 Million USD | 369.045% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 513.495% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 514.664% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 235.578% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1198.159% |
| MediciNova, Inc. | -9.9 Million USD | 3509.747% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 367.125% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 4761.041% |
| GeoVax Labs, Inc. | -26.74 Million USD | 1362.292% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 245.616% |
| Biomea Fusion, Inc. | -126.13 Million USD | 367.629% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 196.615% |
| Mereo BioPharma Group plc | -28.41 Million USD | 1287.972% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 276.658% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 246.801% |
| Absci Corporation | -115.51 Million USD | 392.234% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 1323.671% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 399.09% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 239.4% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 1439.792% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 262.3% |
| Allakos Inc. | -196.05 Million USD | 272.182% |
| Imunon, Inc. | -21.03 Million USD | 1705.169% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 405.044% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -214.66% |
| BioAtla, Inc. | -129.68 Million USD | 360.299% |
| NLS Pharmaceutics AG | -11.8 Million USD | 2959.085% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 2230.745% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 203.001% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 908.406% |
| XOMA Corporation | -41.84 Million USD | 906.667% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 420.775% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 377.85% |
| aTyr Pharma, Inc. | -54.91 Million USD | 714.676% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 486.121% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 295.276% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 232.668% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 1672.599% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 4210.362% |
| Akari Therapeutics, Plc | -16.8 Million USD | 2108.652% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 3817501.954% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 5266.404% |
| UroGen Pharma Ltd. | -65.53 Million USD | 615.097% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 478.116% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 4747.851% |
| Orgenesis Inc. | -53.63 Million USD | 729.38% |
| Entera Bio Ltd. | -8.89 Million USD | 3896.806% |
| GH Research PLC | -41.22 Million USD | 918.917% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 1413.109% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 506.456% |
| Xencor, Inc. | -138.63 Million USD | 343.491% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 6649.007% |
| Replimune Group, Inc. | -234.77 Million USD | 243.787% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 1670.76% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 2519.538% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 5266.404% |
| Portage Biotech Inc. | -18.25 Million USD | 1949.417% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 4761.041% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 421.619% |
| OncoCyte Corporation | -25.13 Million USD | 1442.99% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 3086.097% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 3046.428% |
| Purple Biotech Ltd. | 22.27 Million USD | -1415.756% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 4593.797% |
| scPharmaceuticals Inc. | -55.39 Million USD | 709.383% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 1886.324% |
| HilleVax, Inc. | -133.34 Million USD | 353.158% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 2901.676% |
| Tharimmune, Inc. | -9.45 Million USD | 3670.24% |
| Genprex, Inc. | -31.07 Million USD | 1186.3% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 279.376% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 1175.864% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 44227.32% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 6297.522% |
| OKYO Pharma Limited | -15.74 Thousand USD | 2143463.728% |
| Savara Inc. | -60 Million USD | 662.558% |
| Curis, Inc. | -48.33 Million USD | 798.448% |
| Daré Bioscience, Inc. | -30.83 Million USD | 1194.602% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 6570.306% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 4738.917% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 1338.804% |
| BeiGene, Ltd. | -1.2 Billion USD | 127.951% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 1793.008% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 169.291% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 460.456% |
| Erasca, Inc. | -141.52 Million USD | 338.526% |
| bluebird bio, Inc. | -244.26 Million USD | 238.202% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 7556.946% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -73.613% |
| DBV Technologies S.A. | -76.43 Million USD | 541.666% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 7556.946% |
| Moderna, Inc. | -4.23 Billion USD | 107.964% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 892.26% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 5407.767% |
| Molecular Templates, Inc. | -10.46 Million USD | 3325.435% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 602.066% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 189.603% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 335.553% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 749.268% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 318.435% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 262.194% |
| MacroGenics, Inc. | -168.24 Million USD | 300.645% |
| RenovoRx, Inc. | -11.39 Million USD | 3062.215% |
| Adicet Bio, Inc. | -152.03 Million USD | 322.033% |
| Prime Medicine, Inc. | -191.29 Million USD | 276.471% |
| Aditxt, Inc. | -26.06 Million USD | 1395.252% |
| Adagene Inc. | -23.71 Million USD | 1523.17% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4717.913% |
| Quantum-Si incorporated | -111.17 Million USD | 403.653% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 1166.652% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 2415.677% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -176.668% |
| SciSparc Ltd. | -5.77 Million USD | 5947.462% |
| Vericel Corporation | -6.46 Million USD | 5322.37% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 3999.585% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 1560.122% |
| Generation Bio Co. | -138.56 Million USD | 343.625% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 506.569% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 490.44% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 240.014% |
| Invivyd, Inc. | -207.78 Million USD | 262.465% |
| Relay Therapeutics, Inc. | -373 Million USD | 190.502% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 3699.444% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -1471.5% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 3381.559% |
| 2seventy bio, Inc. | -216.7 Million USD | 255.777% |
| ADMA Biologics, Inc. | 21.63 Million USD | -1460.531% |
| Clene Inc. | -40.54 Million USD | 932.694% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 1502.01% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 716.056% |
| GeoVax Labs, Inc. | -26.74 Million USD | 1362.292% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 196.433% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 1019.018% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -1999.733% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 425.523% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 1092.806% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 298.249% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 149.331% |
| Evaxion Biotech A/S | -22.19 Million USD | 1620.809% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 509.767% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 251.294% |
| Trevena, Inc. | -35.28 Million USD | 1056.625% |
| Surrozen, Inc. | -45.78 Million USD | 837.383% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 522.258% |
| Cingulate Inc. | -22.75 Million USD | 1583.243% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -4405.793% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 855.757% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 4199.786% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 429.154% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 560.042% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 643.825% |
| Clearmind Medicine Inc. | -8.74 Million USD | 3961.806% |
| Kronos Bio, Inc. | -121.83 Million USD | 377.086% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 543.034% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 11609.571% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 434.805% |
| Statera Biopharma, Inc. | -98.34 Million USD | 443.259% |
| ImmunityBio, Inc. | -362.25 Million USD | 193.188% |
| Korro Bio, Inc. | -84.53 Million USD | 499.335% |
| Kineta, Inc. | -15.72 Million USD | 2247.008% |
| BioVie Inc. | -32.17 Million USD | 1149.032% |
| Codexis, Inc. | -68.06 Million USD | 595.929% |
| Celularity Inc. | -192.28 Million USD | 275.557% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 251.645% |
| Celcuity Inc. | -66.23 Million USD | 609.697% |
| Virax Biolabs Group Limited | -6.49 Million USD | 5296.266% |
| Cibus, Inc. | -318.88 Million USD | 205.861% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 885.056% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 1097.441% |
| IN8bio, Inc. | -30.33 Million USD | 1212.747% |
| Kodiak Sciences Inc. | -277.32 Million USD | 221.727% |
| Annexon, Inc. | -143.72 Million USD | 334.878% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 372.697% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 622.189% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 1539.916% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 195.433% |
| Eyenovia, Inc. | -25.4 Million USD | 1428.694% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -934.234% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 6169.292% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 526.591% |
| Arcellx, Inc. | -89.88 Million USD | 475.583% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 843.359% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 346.033% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 1185.133% |
| Moolec Science SA | -6.65 Million USD | 5173.398% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 652.151% |
| Geron Corporation | -193.94 Million USD | 274.057% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 880.464% |
| Royalty Pharma plc | 1.49 Billion USD | 77.377% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 305.635% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 3718.984% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 1641.81% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 297.461% |
| Humacyte, Inc. | -100.04 Million USD | 437.415% |
| Structure Therapeutics Inc. | -102.77 Million USD | 428.459% |
| 89bio, Inc. | -151.2 Million USD | 323.257% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 521.272% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 2421.692% |
| Genelux Corporation | -24.16 Million USD | 1496.954% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 1095.118% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 296.55% |
| Notable Labs, Ltd. | -14.65 Million USD | 2403.159% |
| Liquidia Corporation | -73.38 Million USD | 560.01% |
| Mustang Bio, Inc. | -50.72 Million USD | 765.485% |
| Immunovant, Inc. | -282.7 Million USD | 219.407% |
| Quantum-Si incorporated | -111.17 Million USD | 403.653% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 532.216% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 1687.314% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 430.916% |
| Acasti Pharma Inc. | -11.31 Million USD | 3084.211% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 1572.765% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 2212.563% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 257.705% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 9300.528% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 2224.978% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 1257.78% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 915.711% |
| PepGen Inc. | -84.76 Million USD | 498.242% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 1239.26% |
| United Therapeutics Corporation | 1.18 Billion USD | 71.51% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 1574.315% |
| Solid Biosciences Inc. | -104.31 Million USD | 423.61% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 1128.934% |
| Immuneering Corporation | -58.41 Million USD | 677.91% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 6731.795% |
| Silo Pharma, Inc. | -3.85 Million USD | 8855.439% |
| Belite Bio, Inc | -31.66 Million USD | 1165.978% |
| XOMA Corporation | -41.84 Million USD | 906.667% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 599.961% |
| Bionomics Limited | -17.89 Billion USD | 101.887% |
| Apogee Therapeutics, Inc. | -93 Million USD | 462.971% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -846.115% |
| uniQure N.V. | -282.87 Million USD | 219.338% |
| Cassava Sciences, Inc. | -105.95 Million USD | 418.595% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4717.913% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 360.667% |
| Forte Biosciences, Inc. | -32.48 Million USD | 1139.137% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 4162.871% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 1248.406% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 6169.292% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 2475.609% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 3897.66% |
| Altimmune, Inc. | -95.92 Million USD | 451.9% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 559.322% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -846.115% |
| Compugen Ltd. | -12.99 Million USD | 2698.322% |
| Peak Bio, Inc. | -1356.23 USD | 24890715.898% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 780.538% |
| Benitec Biopharma Inc. | -22.49 Million USD | 1600.996% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 239.319% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 1234.855% |
| Zura Bio Limited | -62.63 Million USD | 638.928% |
| PolyPid Ltd. | -22.86 Million USD | 1576.25% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 2174.06% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 1234.855% |
| Instil Bio, Inc. | -159.16 Million USD | 312.085% |
| argenx SE | -425.04 Million USD | 179.42% |
| Immunome, Inc. | -109.53 Million USD | 408.202% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 770.282% |
| Verona Pharma plc | -67.83 Million USD | 597.67% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 1395.372% |
| Shattuck Labs, Inc. | -91.95 Million USD | 467.1% |
| CervoMed Inc. | -7.81 Million USD | 4420.729% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 561.734% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 2634.149% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 800.739% |
| Moolec Science SA | -6.65 Million USD | 5173.398% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 2152.316% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 349.636% |
| AnaptysBio, Inc. | -164.41 Million USD | 305.323% |
| Design Therapeutics, Inc. | -78.19 Million USD | 531.736% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 487.833% |
| NeurAxis, Inc. | -6.66 Million USD | 5165.26% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 933.537% |
| Lumos Pharma, Inc. | -36.61 Million USD | 1021.981% |
| Achilles Therapeutics plc | -75.25 Million USD | 548.574% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 1395.372% |
| 180 Life Sciences Corp. | -13.47 Million USD | 2604.723% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -6446.812% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 11609.571% |
| Nutriband Inc. | -4.87 Million USD | 7028.964% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 404.725% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 708.801% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 764.045% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 610.71% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 723.715% |
| Palisade Bio, Inc. | -13.07 Million USD | 2682.816% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 843.408% |
| Beam Therapeutics Inc. | -176.48 Million USD | 291.276% |
| Neurogene Inc. | -55.58 Million USD | 707.333% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 409.264% |
| AEON Biopharma, Inc. | -48.42 Million USD | 797.049% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 449.058% |
| Sesen Bio, Inc. | -25.9 Million USD | 1402.922% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 504.14% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 2781.948% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 173.297% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 566.011% |
| Athira Pharma, Inc. | -125.46 Million USD | 369.056% |
| Vaccinex, Inc. | -22.88 Million USD | 1575.088% |
| HCW Biologics Inc. | -25.71 Million USD | 1412.641% |
| XOMA Corporation | -41.84 Million USD | 906.667% |
| Nektar Therapeutics | -137.42 Million USD | 345.642% |
| Arvinas, Inc. | -401.5 Million USD | 184.078% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 3817501.954% |
| Merus N.V. | -156.54 Million USD | 315.637% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 436.695% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 1075.084% |
| Rezolute, Inc. | -70.42 Million USD | 579.352% |
| Clene Inc. | -40.54 Million USD | 932.694% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 2161.083% |
| BeyondSpring Inc. | -23.11 Million USD | 1560.474% |
| Synlogic, Inc. | -55.16 Million USD | 711.979% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 1982.838% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 3218.755% |
| Peak Bio, Inc. | -1356.23 USD | 24890715.898% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 933.454% |
| Krystal Biotech, Inc. | -109.72 Million USD | 407.649% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 360.594% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 198.414% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 7212.881% |
| MannKind Corporation | 8.67 Million USD | -3789.998% |
| Ikena Oncology, Inc. | -75.41 Million USD | 547.61% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 3599.264% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 602.118% |
| Gossamer Bio, Inc. | -183.75 Million USD | 283.705% |
| CohBar, Inc. | -12.38 Million USD | 2824.943% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 765.511% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 1323.671% |
| Legend Biotech Corporation | -439.48 Million USD | 176.811% |
| Mural Oncology plc | -194.63 Million USD | 273.437% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 602.769% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 2190.854% |
| Disc Medicine, Inc. | -91.12 Million USD | 470.452% |
| Champions Oncology, Inc. | -7.35 Million USD | 4689.097% |
| REGENXBIO Inc. | -268.12 Million USD | 225.9% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 3249.544% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 705.449% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 966.449% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 395.193% |
| Vaxart, Inc. | -83.34 Million USD | 505.022% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 4062.132% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 888.833% |
| Cellectis S.A. | -106.62 Million USD | 416.596% |
| Longeveron Inc. | -21.02 Million USD | 1705.278% |
| Repare Therapeutics Inc. | -116.22 Million USD | 390.451% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 226.043% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 546.261% |
| Revolution Medicines, Inc. | -487.18 Million USD | 169.291% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 5174.775% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 868.017% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 552.573% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 584.776% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 3165.789% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 92.163% |
| Denali Therapeutics Inc. | -196.69 Million USD | 271.62% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 3999.585% |
| Veru Inc. | -93.78 Million USD | 459.955% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 1547.014% |
| Cingulate Inc. | -22.75 Million USD | 1583.243% |
| Passage Bio, Inc. | -108.38 Million USD | 411.447% |
| Context Therapeutics Inc. | -25.07 Million USD | 1446.385% |
| Exicure, Inc. | -14.99 Million USD | 2351.094% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 263.82% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 931.504% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 3574.078% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 283.109% |
| Nuvalent, Inc. | -149.49 Million USD | 325.814% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 4208.485% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 480.447% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 1724.983% |
| OmniAb, Inc. | -69.41 Million USD | 586.285% |
| Anew Medical, Inc. | -1.3 Million USD | 26050.463% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 2743.286% |
| Lipocine Inc. | -17.93 Million USD | 1982.632% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 592.715% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 543.29% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 986.595% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 954.034% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 1608.104% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 158.218% |
| Ocugen, Inc. | -65.53 Million USD | 615.136% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 459.634% |
| Q32 Bio Inc. | -92.1 Million USD | 466.522% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 1674.579% |
| Alumis Inc. Common Stock | -158.17 Million USD | 313.419% |
| Equillium, Inc. | -14.52 Million USD | 2424.57% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 640.932% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 4371.278% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1889.409% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 818.992% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 411.226% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 2920.164% |
| Dominari Holdings Inc. | -21.79 Million USD | 1648.789% |
| Edesa Biotech, Inc. | -9.22 Million USD | 3760.228% |
| vTv Therapeutics Inc. | -25.5 Million USD | 1423.716% |
| Bio-Techne Corporation | 206.68 Million USD | -63.327% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 186.229% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -75.792% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 355.202% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 979.305% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 323.41% |
| Nkarta, Inc. | -131.65 Million USD | 356.418% |
| BioCardia, Inc. | -11.64 Million USD | 2999.124% |
| Iterum Therapeutics plc | -47.46 Million USD | 811.161% |